Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Is It Time to Buy MannKind?

Editor's Note: In the video, analyst Michael Douglass incorrectly states that Afrezza had a previous Advisory Committee positive recommendation. Afrezza has not been before an Advisory Committee before this round. The Motley Fool and the analyst regret the error.

MannKind  (NASDAQ: MNKD  ) has been on a tear since the beginning of the year, with the stock up over 50% year to date in large part due to a positive Advisory Committee recommendation for its inhaled insulin drug Afrezza. All eyes are now on the FDA, which has scheduled a Prescription Drug User Fee Action (PDUFA) date of July 15, 2014.

And if the FDA approves the drug, commercialization awaits. MannKind has not yet announced a marketing partner, and Pfizer's past difficulty marketing its own inhaled insulin, Exubera, is enough to give some investors pause.

In the video below, from Wednesday's edition of Where The Money Is, Motley Fool health care analyst Michael Douglass lays out why he is comfortable avoiding the stock for the time being.

Can even MannKind keep up with this top stock?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

Read/Post Comments (21) | Recommend This Article (17)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On May 23, 2014, at 7:11 PM, bluemoth wrote:

    there was no ADCOM for last rejection

  • Report this Comment On May 23, 2014, at 7:17 PM, ferlaylajr wrote:

    Exubera was a 3 foot bong and how do you know they have no partners when they said they are in discussions with multiple partners. How old are you any way? Do you even know what Exubera is?

  • Report this Comment On May 23, 2014, at 7:57 PM, pkane88 wrote:

    JACKASS !!!!!!

  • Report this Comment On May 23, 2014, at 8:13 PM, theeseer wrote:

    Did you not hear the many Doctors testimonies at the Adcom? How many jackasses does it take to make a Motley Fool? Only one, David Williamson. You can join Adam Fuerstine of "The Street" and Piper Jafray's Dr. Schummer in a crow eating contest come July. The winner gets another chance to be "Fool" of the decade when stellar sales are reported in the first quarter of next year. Have you bothered to speak to any Afrezza users from the trial? How about diabetes patients and their thoughts on the ability to reduce or eliminate needle injections? How about emergency room Doctors looking for a faster acting insulin in life and death situations? Wow I guess anyone can be an analyst these days and not have to do due diligence.

  • Report this Comment On May 23, 2014, at 8:13 PM, jesus4profits wrote:

    just like bluemoth stated, Michael DouglASS seems to not have done his homework and thus again proves the guys at MF tend not to know WTH they are talking about. Prior to April 1st of this year, MNKD never had an ADCOMM for Afrezza. This was the first. It is amazing that these guys get paid to misrepresent the facts. Michael DouglASS, you are not very competent.

  • Report this Comment On May 23, 2014, at 8:36 PM, Jim1865 wrote:

    Why do they let idiots like this Michael Douglas speak? Previous AdCom? Sorry there wasn't another. Excubera? Anyone that knows even a little about Afrezza knows it is nothing like Excubra. No partner? How the hell do you know Mikey? A partner probably will not be announced until after the label is known. Mikey Boy, do you really think Afrezza is not going to be approved? Well then go ahead and short it. It is one thing to be wrong and entirely another to not have a clue what you are talking about. Moron.

    Well at least I will know not to bother to read anything on this site in the future. It looks like they just let ill informed kids spout off misinformation.

  • Report this Comment On May 23, 2014, at 8:45 PM, bufnyfan1 wrote:

    Nothing angers me more than when these "advisors" mention Exubera in any article concerning Afrezza---I immediate stop listening and turn this off----THERE IS NO COMPARISON!!! and to insinuate that the failure of Exubera may affect approval of Afrezza is moronic at the very least-I suggest these individuals go back to arguing about soybean futures or pork bellies!!!

  • Report this Comment On May 23, 2014, at 8:49 PM, jesus4profits wrote:

    I can only think that these two knowingly stated false information to get a reaction. The best thing to do as I am going to do after this last post is to boycott this pathetic website. You should do the same. Stop visiting and stop posting.

  • Report this Comment On May 23, 2014, at 9:31 PM, b4unewme2 wrote:

    Give him a pass, he's just young and stupid. There's no crime in that. If you see his profile, young Douglas has zero followers; which pretty much sums up his expertise on Mannkind.

  • Report this Comment On May 23, 2014, at 11:16 PM, justan wrote:

    Okay - so does anyone know outlook for mnkd? Thought FDA was going to approve and lost big time - remember FDA committee was approving etc. Looser again?

  • Report this Comment On May 23, 2014, at 11:18 PM, Obamayoumama wrote:

    Michael, best to know what you speaking of before go on a public interview. It has been said before, but this WAS the first Adcomm. Second, you probably still believe that Tesla will fail because GM EV1 failed. If GM failed at electric cars then how would Tesla sell any cars. Heck they don't have dealerships. Now I know why they call you guys fools.

  • Report this Comment On May 23, 2014, at 11:28 PM, hansvro wrote:

    This is so embarrassing

    What is Michael going to do after this. Go hiding and change jobs? With so many mistakes as pointed out above.

    Definitely no previous adcoms. Exubera can be a point of discussion but extremely superficially dealt with. And then MNKD is going to do this alone? Did he not read anything about the company? EMBARRASSING

    Embarrassing, shameful, sorry to say also to MF. What is MF going to do about such a flop?

  • Report this Comment On May 24, 2014, at 4:45 AM, d52z52 wrote:

    OMG, I can not stop laughing. Are they serious? Was this a grade school project or something? Maybe this was meant to be a joke. You know, like making fun of stock analysts or something like that. Omg, Omg, give me a break.

  • Report this Comment On May 24, 2014, at 6:55 AM, miaaway wrote:

    Need I say anything, Michael is also my first name. Think I'm going to change it so no one gets me mixed up with this idiot,

  • Report this Comment On May 25, 2014, at 9:05 AM, VLN wrote:

    Oh my! How much does one need get paid to make such a fool out of themselves?? Is this all the shorts have left in the tank?

  • Report this Comment On May 26, 2014, at 11:38 AM, Zmoney wrote:

    I'm sick of these so called expert talking out of their rear end. they don't even bother to check the facts just spread their bias opinion....

  • Report this Comment On May 26, 2014, at 6:59 PM, Tan777 wrote:

    On the Exubera comment This is like saying.. Well, Sony was not that successful with the Walkman, therefore Apple will never be successful with the iPod...

    I have no problem with someone giving an opinion that is different than mine, but I am frustrated when someone that is supposed to be an expert gives such a biased and not documented opinion about something the person does not know anything about. This is like having a scientist falsifying information on a clinical trial. With all due respect, this person is a liability to The Motely Fool.

  • Report this Comment On May 27, 2014, at 9:58 AM, fuzzface52 wrote:

    @Justin why do you even post anything if you can not spell? The word is "Loser" and from your lack of spelling that is exactly what you are! Go back to school you loser and stop investing in stocks!.

  • Report this Comment On May 27, 2014, at 10:04 AM, fuzzface52 wrote:

    @ Michael Douglas to bad your not the actor because you suck at being an analyst. Then again you do work for the Motley Fool so you need not worry to much about sucking because everyone there does. Company should be named the Motley Ignorance for their lack of understand of what they do.

  • Report this Comment On May 28, 2014, at 3:00 PM, hattrick wrote:

    The size and subsequent awkwardness of the previous inhaler from PFE was significant. Lung suppression is negligible, inconsequential. The last clinical trial was a "generic" trial to demonstrate the equivalency of the more recent inhaler produced similar results to the older version. Since Exubera, these tiny particle inhalers have become common for asthma and COPD steroid devices, making the likelihood of patient acceptance very positive. I expect a slow product launch, but ultimately very successful multibillion dollar sales. The three billion dollar market cap reflects some uncertainty associated with the introduction.

  • Report this Comment On May 30, 2014, at 8:33 PM, Jim1865 wrote:

    Hey Mikey Boy! How's that short positions treating you? Moron.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2970651, ~/Articles/ArticleHandler.aspx, 9/3/2015 12:43:54 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Michael Douglass

As the Motley Fool's Health Care Editor/Analyst, I focus on all things health care -- although my greatest interest is in the megatrends reshaping the American health care system, including the Affordable Care Act, Accountable Care Organizations, a shifting regulatory landscape, and the new drug discoveries fundamentally changing disease management and treatment.

Today's Market

updated 3 hours ago Sponsored by:
DOW 16,351.38 293.03 1.82%
S&P 500 1,948.86 35.01 1.83%
NASD 4,749.98 113.87 2.46%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/2/2015 4:00 PM
MNKD $3.85 Up +0.14 +3.77%
MannKind Corp CAPS Rating: **